Get the Stockscreener App
1.74
1.16%
0.02
Essa Pharma Inc stock is traded at $1.74, with a volume of 338.52K.
It is up +1.16% in the last 24 hours and down -71.38% over the past month.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
See More
Previous Close:
$1.72
Open:
$1.72
24h Volume:
338.52K
Relative Volume:
0.44
Market Cap:
$75.02M
Revenue:
-
Net Income/Loss:
$-25.80M
P/E Ratio:
-2.8065
EPS:
-0.62
Net Cash Flow:
$-22.19M
1W Performance:
-2.79%
1M Performance:
-71.38%
6M Performance:
-69.47%
1Y Performance:
-67.23%
1-Day Range:
$1.66
$1.74
1-Week Range:
$1.66
$1.89
52-Week Range:
$1.40
$11.67
Essa Pharma Inc Stock (EPIX) Company Profile
Name
Essa Pharma Inc
Sector
Industry
Phone
(778) 331-0962
Address
SUITE 720, VANCOUVER, BC
Compare EPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| EPIX | 1.735 | 75.02M | 0 | -25.80M | -22.19M | -0.62 |
| VRTX | 467.39 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 761.21 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 566.22 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.85 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.60 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Essa Pharma Inc Stock (EPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-04-21 | Initiated | Piper Sandler | Overweight |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-25-19 | Initiated | Oppenheimer | Outperform |
Essa Pharma Inc Stock (EPIX) Latest News
PFM Health Sciences, LP Adjusts Stake in ESSA Pharma Inc - GuruFocus.com
RTW INVESTMENTS, LP Acquires Shares in ESSA Pharma Inc - GuruFocus.com
ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
ESSA Pharma And 2 Other US Penny Stocks To Watch - Yahoo Finance
Jones Trading Downgrades ESSA Pharma (EPIX) - MSN
ESSA Pharma (NASDAQ:EPIX) Lowered to Market Perform Rating by Oppenheimer - Defense World
ESSA Pharma (NASDAQ:EPIX) Rating Lowered to Neutral at Piper Sandler - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Growth N. V. Biotech Sells 7,879,583 Shares of ESSA Pharma Inc. (NASDAQ:EPIX) Stock - MarketBeat
Bb biotech ag sells Essa Pharma shares for $12 million - Investing.com
Bb biotech ag sells Essa Pharma shares for $12 million By Investing.com - Investing.com UK
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ESSA Pharma shares downgraded after halting drug development By Investing.com - Investing.com Canada
ESSA Pharma terminates vital trial, leading Piper Sandler to cut shares rating - Investing.com Canada
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials - Investing.com Canada
Jefferies Financial Group Downgrades ESSA Pharma (NASDAQ:EPIX) to Hold - MarketBeat
Piper Sandler Downgrades ESSA Pharma (EPIX) - MSN
2024-11-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect | NDAQ:EPIX | Press Release - Stockhouse Publishing
Michael Jenson, PA-C, on Minnesota Urology’s Surgical Impotence Management Strategy program - Urology Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect - AccessWire
ESSA Pharma tank as it drops Phase II masofaniten study - The Pharma Letter
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
ESSA Pharma stock plunges to 52-week low of $1.55 - Investing.com India
ESSA Pharma stock plunges to 52-week low of $1.55 By Investing.com - Investing.com South Africa
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
United States shares higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Essa ends prostate cancer bid, seeks strategic options - BioWorld Online
ESSA Pharma tanks after terminating trial for its prostate cancer treatment - MSN
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results - Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results - Benzinga
ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC - OncLive
Dow Jumps 400 Points; US Adds 12,000 Jobs In October - Benzinga
Jones Trading cuts ESSA Pharma shares to hold from buy on trial data - Investing.com Australia
Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade - Barchart
Why Is ESSA Pharma Stock Plunging On Friday?ESSA Pharma (NASDAQ:EPIX) - Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
ESSA Pharma tanks after terminating trial for its prostate cancer treatment (NASDAQ:EPIX) - Seeking Alpha
Jones Trading cuts ESSA Pharma shares to hold from buy on trial data By Investing.com - Investing.com South Africa
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment - Yahoo Finance
Essa Pharma Shares Drop After Lead Drug Candidate Fails - MarketWatch
ESSA Pharma (NASDAQ:EPIX) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - VictoriaNow
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - StockTitan
When the Price of (EPIX) Talks, People Listen - Stock Traders Daily
ESSA Pharma Insiders Placed Bullish Bets Worth US$709.0k - Yahoo Finance
ESSA Pharma Insiders Added US$709.0k Of Stock To Their Holdings - Simply Wall St
ESSA Pharma (NASDAQ:EPIX) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Centessa Pharmaceuticals (CNTA) - RTTNews
Essa Pharma Inc Stock (EPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Essa Pharma Inc Stock (EPIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Virsik Peter | Chief Operating Officer |
Oct 07 '24 |
Sale |
6.03 |
694 |
4,185 |
7,776 |
| Virsik Peter | Chief Operating Officer |
Sep 09 '24 |
Sale |
6.00 |
694 |
4,164 |
8,470 |
| Virsik Peter | Chief Operating Officer |
Sep 03 '24 |
Sale |
6.03 |
2,082 |
12,554 |
9,164 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):